Saint Louis University vaccine and treatment trials center
Official title: Vaccine and Treatment Evaluation Unit at Saint Louis University
Funded at Saint Louis University · NIH-11283980 · Data updated 2026-11-12
This SLU program runs vaccine and treatment trials for infectious diseases, including biodefense threats like anthrax, and enrolls adults in early-to-late phase studies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 11, 2019 |
| Project end | November 30, 2026 |
| Funding year | 2026 |
| Award (this year) | $2 |
| NIH project number | 5UM1AI148685-07 |
| Project ID | NIH-11283980 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (commonly 21 years and older) who meet the trial's health and eligibility criteria, including healthy volunteers and some special populations, are the ideal candidates.
✕Less likely to help
People under the age requirement, those who do not meet medical eligibility, or those seeking guaranteed personal therapeutic benefit may not receive direct benefit from participation.
What this research studies
You can join vaccine and therapeutic trials run at Saint Louis University that cover phase I–IV studies for adults and some special populations. Trials combine clinic visits, medical exams, blood draws, laboratory testing, and multi‑platform 'omics' to track immune responses and safety. SLU is part of a national Vaccine and Treatment Evaluation Unit (VTEU) network and has experience with influenza, tuberculosis, malaria, and urgent biodefense trials such as anthrax. Studies include both planned development trials and rapid-response trials during outbreaks or public health emergencies.
Why it matters
Potential benefit: Participation could provide early access to new vaccines or treatments and help advance prevention and care for infections like anthrax.
How similar studies have gone: VTEU sites have previously advanced successful vaccine trials for infections such as influenza, though work on new biodefense vaccines like anthrax remains challenging and ongoing.
Where this research is happening
-
Saint Louis University
Saint Louis, United States Active
Researchers
- Principal investigator: Hoft, Daniel F. — Saint Louis University
- Study coordinator: Hoft, Daniel F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.